SEC Form 4 · accession 0001209191-17-052601
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Moze
Officer — EVP, Chief Admin. Officer
Period of report
Sep 12, 2017
Accepted (ET)
Sep 13, 2017 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Sep 12, 2017 | M | 3,925 | — | A | 67,951 | D | |
| Ordinary Shares | Sep 12, 2017 | F | 1,841 | $13.42 | D | 66,110 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Sep 12, 2017 | M | 3,925 | D | — | — | Ordinary Shares | 3,925 | 3,925 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2Includes 1,429 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program.
- F3The restricted stock units vest in four annual installments of 3,925 shares, on each anniversary of the vesting commencement date (September 12, 2014).